Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Operating Expenses (2023 - 2026)

Compass Therapeutics' Operating Expenses history spans 4 years, with the latest figure at $20.3 million for Q1 2026.

  • On a quarterly basis, Operating Expenses rose 12.99% to $20.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $75.2 million, a 19.94% increase, with the full-year FY2025 number at $72.8 million, up 26.73% from a year prior.
  • Operating Expenses hit $20.3 million in Q1 2026 for Compass Therapeutics, up from $18.0 million in the prior quarter.
  • Over the last five years, Operating Expenses for CMPX hit a ceiling of $21.1 million in Q2 2025 and a floor of $9.7 million in Q1 2023.
  • Historically, Operating Expenses has averaged $15.5 million across 4 years, with a median of $15.8 million in 2025.
  • Biggest five-year swings in Operating Expenses: increased 2.62% in 2024 and later surged 40.69% in 2025.
  • Tracing CMPX's Operating Expenses over 4 years: stood at $15.4 million in 2023, then increased by 7.67% to $16.6 million in 2024, then rose by 8.54% to $18.0 million in 2025, then rose by 12.83% to $20.3 million in 2026.
  • Business Quant data shows Operating Expenses for CMPX at $20.3 million in Q1 2026, $18.0 million in Q4 2025, and $15.8 million in Q3 2025.